1. Aicher A, Sindrilaru A, Crisan D, Thaiss W, Steinacker J, Beer M, Wiegel T, Scharffetter-Kochanek K, Beer AJ, Prasad V. Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma. Pharmaceutics. 2022 Jul 14;14(7):1466. doi:10.3390/pharmaceutics14071466. PMID: 35890361; PMCID: PMC9323617.
  2. Assadi M, Manafi-Farid R, Jafari E, Keshavarz A, Divband G, Moradi MM, Adinehpour Z, Samimi R, Dadgar H, Jokar N, Mayer B, Prasad V. Predictive and prognostic potential of pretreatment Ga-68-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA. Front Oncol 2022; 12: 10.
  3. Boss M, Rottenburger C, Brenner W, Blankenstein O, Prasad V, Prasad S, de Coppi P, Kühnen P, Buitinga M, Nuutila P, Otonkoski T, Hussain K, Brom M, Eek A, Bomanji JB, Shah P, Gotthardt M. (68)Ga-NODAGA-exendin-4 PET improves the detection of focal congenital hyperinsulinism. J Nucl Med 2022; 63: 310-5
  4. Dromain C, Vullierme M, Hicks R, Prasad V, O’Toole D, de Herder W, Pavel M, Faggiano A, Kos-Kudla B, Öberg K, Krejs G, Grande E, Niederle B, Sundin A. ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours. Journal of Neuroendocrinology 2022; 34: e13044
  5. Eberhardt N, Peters L, Kapp-Schwoerer S, Beer M, Beer AJ, Grüner B, Thaiss WM. 18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting. Pathogens. 2022 Mar 12;11(3):348. doi:10.3390/pathogens11030348. PMID: 35335672; PMCID: PMC8951377.
  6. Ekert K, Kloth C, Nikolaou K, Grözinger G, Horger M, Thaiss W. Rim Enhancement after Technically Successful Transarterial Chemoembolization in Hepatocellular Carcinoma: A Potential Mimic of Incomplete Embolization or Reactive Hyperemia? Tomography. 2022 Apr 15;8(2):1148-1158. doi:10.3390/tomography8020094. PMID: 35448728; PMCID: PMC9028792.
  7. Glatting G, Beer AJ, Kull T, Winter G. Obituary of Dr. biol. hum. Peter Kletting. Nuklearmedizin-Nuclear Medicine 2022; 61: 132.
  8. Grozinsky-Glasberg S, Davar J, Hofland J, Dobson R, Prasad V, Pascher A, Denecke T, Tesselaar MET, Panzuto F, Albage A, Connolly HM, Obadia JF, Riechelmann R, Toumpanakis C. European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease. J Neuroendocrinol 2022; 34: 16.
  9. Hagen F, Norz V, Thaiss WM, Mair A, Rausch S, Bedke J, Nikolaou K, Stenzl A, Kruck S, Hepp T, Kaufmann S, Estler A. Diagnostic benefit of multiparametric MRI over contrast-enhanced CT in patients with bladder cancer: A single-center 1-year experience. Eur J Radiol 2022; 146: 110059.
  10. Hagen F, Peisen F, Spogis J, Mair A, Nikolaou K, Stenzl A, Kruck S, Bedke J, Kaufmann S, Thaiss WM. Is a single portal venous phase in contrast-enhanced CT sufficient to detect metastases or recurrence in clear cell renal cell carcinoma? - a single-center retrospective study. Cancer Imaging 2022; 22: 9.
  11. Hepp T, Kalmbach L, Kolb M, Martirosian P, Hilbert T, Thaiss WM, Notohamiprodjo M, Bedke J, Nikolaou K, Stenzl A, Kruck S, Kaufmann S. T2 mapping for the characterization of prostate lesions. World J Urol. 2022 Jun;40(6):1455-1461. doi: 10.1007/s00345-022-03991-8. Epub 2022 Mar 31. PMID: 35357510; PMCID: PMC9166840.
  12. Hicks RJ, Dromain C, de Herder WW, Costa FP, Deroose CM, Frilling A, Koumarianou A, Krenning EP, Raymond E, Bodei L, Sorbye H, Welin S, Wiedenmann B, Wild D, Howe JR, Yao J, O’Toole D, Sundin A, Prasad V. ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. Journal of Neuroendocrinology 2022; 34: e13040.
  13. Hofland J, Lamarca A, Steeds R, Toumpanakis C, Srirajaskanthan R, Riechelmann R, Panzuto F, Frilling A, Denecke T, Christ E, Grozinsky-Glasberg S, Davar J, Force TECHDT. Synoptic Reporting of Echocardiography in Carcinoid Heart Disease (ENETS Carcinoid Heart Disease task force). J Neuroendocrinology 2022; 34: e13060
  14. Hotz JF, Peters L, Kapp-Schwörer S, Theis F, Eberhardt N, Essig A, Grüner B, Hagemann JB. Evaluation of Serological Markers in Alveolar Echinococcosis Emphasizing the Correlation of PET-CTI Tracer Uptake with RecEm18 and Echinococcus-Specific IgG. Pathogens 2022; 11.
  15. Juengling FD, Wuest F, Kalra S, Agosta F, Schirrmacher R, Thiel A, Thaiss W, Muller HP, Kassubek J. Simultaneous PET/MRI: The future gold standard for characterizing motor neuron disease-A clinico-radiological and neuroscientific perspective. Front Neurol 2022; 13: 14.
  16. Kloth C, Brunner H, Vogele D, Beck A, Schonsteiner S, Beer AJ, Beer M, Thaiss WM. Tumor of the right atrium with disseminated pulmonal metastases. Radiologie 2022; 62: 870-4.
  17. Kloth C, Schmidt SA, Graeter T, Nikolaou K, Kaufmann S, Beer M, Thaiss WM. Evaluation of an elective ultrasound course for medical students. Clin Anat. 2022 Apr;35(3):354-358. doi: 10.1002/ca.23838. Epub 2022 Feb 8. PMID: 35128729.
  18. Kloth C, Thaiss WM, Beer M, Bösmüller H, Baumgartner K, Fritz J, Horger M. The many faces of cryptogenic organizing pneumonia (COP). J Clin Imaging Sci. 2022 Jun 3;12:29. doi: 10.25259/JCIS_208_2021. PMID: 35769096; PMCID: PMC9235424.
  19. Kolade OU, Ayeni AO, Brink A, Steyn R, More S, Prasad V. SARS-CoV-2 vaccination site as possible pitfall on somatostatin receptor imaging. Clin Transl Imaging 2022; 10: 579-85.
  20. Kuhn Cuellar L, Friedrich A, Gabernet G, de la Garza L, Fillinger S, Seyboldt A, Koch T, Zur Oven-Krockhaus S, Wanke F, Richter S, Thaiss WM, Horger M, Malek N, Harter K, Bitzer M, Nahnsen S. A data management infrastructure for the integration of imaging and omics data in life sciences. BMC Bioinformatics. 2022 Feb 7;23(1):61. doi: 10.1186/s12859-022-04584-3. PMID: 35130839; PMCID: PMC8822871.
  21. Langbein T, Kulkarni HR, Schuchardt C, Mueller D, Volk GF, Baum RP. Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with Lu-177-PSMA and Combined Ac-225- and Lu-177-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation. Diagnostics 2022; 12: 15.
  22. Lapa C, Nestle U, Albert NL, Baues C, Beer A, Buck A, Budach V, Butof R, Combs SE, Derlin T, Eiber M, Fendler WP, Furth C, Gani C, Gkika E, Grosu AL, Henkenberens C, Ilhan H, Lock S, Marnitz-Schulze S, Miederer M, Mix M, Nicolay NH, Niyazi M, Pottgen C, Rodel CM, Schatka I, Schwarzenboeck SM, Todica AS, Weber W, Wegen S, Wiegel T, Zamboglou C, Zips D, Zophel K, Zschaeck S, Thorwarth D, Troost EGC. Value of PET imaging for radiation therapy *. Nuklearmedizin-Nuclear Medicine 2022: 18.
  23. Lim W, Acker G, Hardt J, Kufeld M, Kluge A, Brenner W, Conti A, Budach V, Vajkoczy P, Senger C, Prasad V. Dynamic (18)F-FET PET/CT to differentiate recurrent primary brain tumor and brain metastases from radiation necrosis after single-session robotic radiosurgery. Cancer Treat Res Commun 2022; 32: 100583.
  24. Lingl JP, Bohm F, Wiegel T, Beer AJ, Hoffmann TK. PSMA-PET-MRI and radio-guided surgery in cervical lymphadenectomy. Hno 2022; 70: 907-10.
  25. Lisson CS, Lisson CG, Mezger MF, Wolf D, Schmidt SA, Thaiss WM, Tausch E, Beer AJ, Stilgenbauer S, Beer M, Goetz M. Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma. Cancers (Basel). 2022 Apr 15;14(8):2008. doi: 10.3390/cancers14082008. PMID: 35454914; PMCID: PMC9028737.
  26. Lisson CS, Lisson CG, Achilles S, Mezger MF, Wolf D, Schmidt SA, Thaiss WM, Bloehdorn J, Beer AJ, Stilgenbauer S, Beer M, Götz M. Longitudinal CT Imaging to Explore the Predictive Power of 3D Radiomic Tumour Heterogeneity in Precise Imaging of Mantle Cell Lymphoma (MCL). Cancers (Basel) 2022; 14: 393
  27. Löffler J, Herrmann H, Scheidhauer E, Wirth M, Wasserloos A, Solbach C, Glatting G, Beer AJ, Rasche V, Winter G. Blocking Studies to Evaluate Receptor-Specific Radioligand Binding in the CAM Model by PET and MR Imaging. Cancers (Basel) 2022; 14
  28. Lopci E, Prasad V. Response assessment of radioligand therapies. Front Oncol 2022; 12: 3.
  29. Lule D, Michels S, Finsel J, Braak H, Del Tredici K, Strobel J, Beer AJ, Uttner I, Muller HP, Kassubek J, Juengling FD, Ludolph AC. Clinicoanatomical substrates of selfish behaviour in amyotrophic lateral sclerosis - An observational cohort study. Cortex 2022; 146: 261-70.
  30. Meyer C, Prasad V, Stuparu A, Kletting P, Glatting G, Miksch J, Solbach C, Lueckerath K, Nyiranshuti L, Zhu S, Czernin J, Beer AJ, Slavik R, Calais J, Dahlbom M. Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225. EJNMMI Research 2022; 12: 65
  31. Müller D, Herrmann H, Solbach C, Li MS, Liu DJ, Beer A, Schultz M, Prasad V. Radiopharmaceutical Production of Pb-203 VMT-alpha-NET for Clinical Use. J Nucl Med 2022; 63: 10.
  32. Parihar AS, Chopra S, Prasad V. Nephrotoxicity after radionuclide therapies. Transl Oncol 2022; 15: 101295
  33. Prasad V, Boss M, Rottenburger C, Brenner W, Blankenstein O, Prasad S, Buitinga M, Shah P, Gotthardt M. Reply: (68)Ga NODAGA-Exendin-4 PET Scanning for Focal Congenital Hyperinsulinism: Need for Replication. J Nucl Med 2022; 63: 493-4.
  34. Rinscheid A, Janzen T, Alikhani B, Beer AJ, Braune A, Eberhardt N, Fechner D, Förster S, Freesmeyer M, Furth C, Grunert M, Hellwig D, Costa PF, Kühnel C, Lange C, Linke R, Razlaw N, Sack T, Schmidt D, Schütze C, Starke A, Tondera L, Wengenmair H, Zöphel K, Burchert W, Lapa C. Radiation doses from low-dose CT scans in SPECT/CT and PET/CT examinations: A survey in Germany. Nuklearmedizin 2022; 61: 294-300.
  35. Schuchardt C, Zhang J, Kulkarni HR, Chen X, Müller D, Baum RP. Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry. J Nucl Med 2022 63:1199-1207 (10.2967/jnumed.121.262713).
  36. Sollmann N, Beer AJ, Kirchhoff F. SARS-CoV-2 infection and the brain: direct evidence for brain changes in milder cases. Signal Transduct Target Ther 2022; 7: 3.
  37. Thaiss WM, Moser S, Hepp T, Kruck S, Rausch S, Scharpf M, Nikolaou K, Stenzl A, Bedke J, Kaufmann S. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy. World J Urol 2022; 40: 2431-8.
  38. Wakileh GA, Ruf C, Heidenreich A, Dieckmann KP, Lisson C, Prasad V, Bolenz C, Zengerling F. Contemporary options and future perspectives: three examples highlighting the challenges in testicular cancer imaging. World J Urol 2022; 40: 307-15.
  39. Winter G, Eberhardt N, Löffler J, Raabe M, Alam MNA, Hao L, Abaei A, Herrmann H, Kuntner C, Glatting G, Solbach C, Jelezko F, Weil T, Beer AJ, Rasche V. Preclinical PET and MR Evaluation of 89Zr- and 68Ga-Labeled Nanodiamonds in Mice over Different Time Scales. Nanomaterials 2022; 12: 4471
  40. Yousefzadeh-Nowshahr E, Winter G, Bohn P, Kneer K, von Arnim CAF, Otto M, Solbach C, Anderl-Straub S, Polivka D, Fissler P, Strobel J, Kletting P, Riepe MW, Higuchi M, Glatting G, Ludolph A, Beer AJ, for the Alzheimer’s Disease Neuroimaging I. Quantitative analysis of regional distribution of tau pathology with 11C-PBB3-PET in a clinical setting. PLOS ONE 2022; 17: e0266906
  41. Zaid NRR, Kletting P, Winter G, Beer AJ, Glatting G. A Whole-Body Physiologically Based Pharmacokinetic Model for Alpha Particle Emitting Bismuth in Rats. Cancer Biother Radiopharm 2022; 37: 41-6.
  42. Zippel C, Ermert J, Patt M, Gildehaus FJ, Ross TL, Reischl G, Kuwert T, Solbach C, Neumaier B, Kiss O, Mitterhauser M, Wadsak W, Schibli R, Kopka K. Cyclotrons Operated for Nuclear Medicine and Radiopharmacy in the German Speaking D-A-CH Countries: An Update on Current Status and Trends. Front Nucl Med 2022; 2.
  43. Zwirtz K, Hardt J, Acker G, Baur ADJ, Pavel M, Huang K, Brenner W, Prasad V. Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT. Pharmaceutics 2022; 14: 15.